Avantor, Inc. logo

Avantor, Inc.

AVTR

NYSEHealthcareMedical - Instruments & Supplies

Previous close

$14.46

+$0.21 · +1.47%

Aug 21, 4:00 PM ET

AVTR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

20

Overpriced

Momentum

51

Neutral

Sentiment

54

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Emmanuel Ligner
Listed since
May 17, 2019
Employees
13,500

Market position

Day range

Current $14.46

52-week range

Current $14.46

Open
$14.245
Previous close
$14.25
Volume
5.22M
0.52× average
Average volume
10.1M
Average daily volume
Market cap
9.78B USD
Beta
0.89
Market reference 1
50-day average
$11.6116
+24.53% above average
200-day average
$10.2099
+41.63% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
11.35B USD
P/E (TTM)
-17.24×
P/B (TTM)
1.74×
P/S (TTM)
1.49×
EV / EBITDA
81.84×
Earnings yield
-6.82%
Free cash flow yield
6.37%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
31.83%
Operating margin
-4.35%
Net margin
-8.81%
Return on equity
-9.53%
Return on assets
-4.50%
Return on invested capital
-2.36%

Financial health

Debt / equity
0.66×
Current ratio
1.78×

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+5.16%
11 comparable reports
Latest EPS result
0.21
Estimate 0.19 · Beat by 9.66%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.310.250.190.13Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 7, 2025: actual 0.27, estimate 0.25, surprise +8.00%, Beat. Q2 2025, reported Apr 25, 2025: actual 0.23, estimate 0.231, surprise -0.61%, Miss. Q3 2025, reported Aug 1, 2025: actual 0.24, estimate 0.25, surprise -4.00%, Miss. Q4 2025, reported Oct 29, 2025: actual 0.22, estimate 0.225, surprise -2.14%, Miss. Q1 2026, reported Feb 11, 2026: actual 0.22, estimate 0.21, surprise +4.76%, Beat. Q2 2026, reported Apr 29, 2026: actual 0.17, estimate 0.157, surprise +8.28%, Beat. Q3 2026, reported Jul 29, 2026: actual 0.21, estimate 0.192, surprise +9.66%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.76B1.66B1.57B1.47BQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 7, 2025: actual 1.69B USD, estimate 1.66B USD, surprise +1.42%, Beat. Q2 2025, reported Apr 25, 2025: actual 1.58B USD, estimate 1.61B USD, surprise -1.64%, Miss. Q3 2025, reported Aug 1, 2025: actual 1.68B USD, estimate 1.65B USD, surprise +2.26%, Beat. Q4 2025, reported Oct 29, 2025: actual 1.62B USD, estimate 1.65B USD, surprise -1.34%, Miss. Q1 2026, reported Feb 11, 2026: actual 1.66B USD, estimate 1.64B USD, surprise +1.61%, Beat. Q2 2026, reported Apr 29, 2026: actual 1.58B USD, estimate 1.54B USD, surprise +2.54%, Beat. Q3 2026, reported Jul 29, 2026: actual 1.69B USD, estimate 1.61B USD, surprise +5.07%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 1.64B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.78

25.45% downside
Past 12 months12-month forecastHigh $14.00Average $10.78Low $7.00

AVTR peers

ETFs holding AVTR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research AVTR

research.disclaimer